Age Related Macular Degeneration 8 C3151070
Age-related macular degeneration (AMD) causes gradual central vision loss by affecting the macula. It mainly occurs in older adults and is treated with approaches to manage vision changes.
Key facts at a glance
- ICD-10
- H53.9
- ICD-11
- 9A00.0
- Body system
- ophthalmologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(ophthalmologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Need for increased lighting when reading
(ophthalmologic)Reduced visual acuity
(ophthalmologic)Difficulty recognizing faces
(ophthalmologic)Decreased contrast sensitivity
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination anti-VEGF protocol
Multi-agent approach using different anti-VEGF medications sequentially or in combination to optimize treatment response in refractory cases.
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Low vision rehabilitation
Specialized training with magnification devices, specialized lighting, and adaptive technologies to maximize functional vision for daily activities.
Additional treatment options
Submacular surgery
Surgical removal of choroidal neovascular membranes and hemorrhage through retinal access, reserved for select cases.
surgicalOmega-3 fatty acid supplementation
Docosahexaenoic acid and eicosapentaenoic acid supplementation supporting retinal cell membrane health and anti-inflammatory pathways.
dietaryVision orientation and mobility training
Specialized physical therapy focusing on safe navigation, fall prevention, and environmental adaptation for visually impaired individuals.
physical_therapyWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Age Related Macular Degeneration 8 C3151070?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Solomon SD, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. Cochrane Database Syst Rev. 2022.
Rosenfeld PJ, et al. Ranibizumab for neovascular age-related macular degeneration: ANCHOR study results. N Engl J Med. 2006.
Mitchell P, et al. Age-related macular degeneration. Lancet. 2018.
American Academy of Ophthalmology. Age-Related Macular Degeneration Preferred Practice Pattern Guidelines. Ophthalmology. 2023.
Medication Comparisons
Compare medications used to treat Age Related Macular Degeneration 8 C3151070. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy